Literature DB >> 10491307

Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein.

T Heintges1, J zu Putlitz, J R Wands.   

Abstract

The monoclonal antibody C7-50 binds to the HCV core protein with high sensitivity and specificity. The coding sequences of the variable domains of the antibody were determined following cDNA cloning of the Fab and sFv fragments. Subsequently, intracellular expression and binding of these antibody fragments to the HCV core protein as a potential antiviral approach were studied. There was high specificity and sensitivity of binding of bacterially expressed, recombinant C7-50 Fab to HCV core as measured by EIA and immunoblot. For expression in mammalian cells, the C7-50 antibody was subcloned in the sFv format by the introduction of a (Gly(4)Ser)(3) linker spaced between light and heavy chains. Northern and Western blot analysis as well as confocal microscopy established the targeted expression of the C7-50 sFv antibody fragment in the endoplasmic reticulum of transfected cells. The colocalization and intracellular binding of the antibody fragment to HCV core protein was confirmed by immunoprecipitation and subsequent immunoblot analysis. This study demonstrates that gene delivery of cDNA coding sequences inducing intracellular expression of C7-50 antibody fragments leads to binding of the antibody fragment to the HCV core protein within the secretory compartment of transfected cells. Intracellular immunization represents a promising antiviral approach to interfere with the life cycle of HCV. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491307     DOI: 10.1006/bbrc.1999.1350

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  The production and application of single-chain antibody fragments.

Authors:  D Blazek; V Celer
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

2.  Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.

Authors:  Juliane Karthe; Kathi Tessmann; Jisu Li; Raiki Machida; Maaike Daleman; Dieter Häussinger; Tobias Heintges
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

3.  Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Authors:  Meital Gal-Tanamy; Romy Zemel; Larissa Bachmatov; Rohit K Jangra; Assaf Shapira; Rodrigo A Villanueva; Minkyung Yi; Stanley M Lemon; Itai Benhar; Ran Tur-Kaspa
Journal:  Antiviral Res       Date:  2010-08-10       Impact factor: 5.970

4.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 5.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

6.  Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity.

Authors:  Michela Flego; Aldo Frau; Luisa Accardi; Alessandra Mallano; Alessandro Ascione; Mara Gellini; Elisa Fanunza; Stefano Vella; Paola Di Bonito; Enzo Tramontano
Journal:  BMC Biotechnol       Date:  2019-09-05       Impact factor: 2.563

Review 7.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

Review 8.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.